Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker
Standard
Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. / Scorilas, Andreas; Borgoño, Carla A; Harbeck, Nadia; Dorn, Julia; Schmalfeldt, Barbara; Schmitt, Manfred; Diamandis, Eleftherios P.
in: J CLIN ONCOL, Jahrgang 22, Nr. 4, 15.02.2004, S. 678-85.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker
AU - Scorilas, Andreas
AU - Borgoño, Carla A
AU - Harbeck, Nadia
AU - Dorn, Julia
AU - Schmalfeldt, Barbara
AU - Schmitt, Manfred
AU - Diamandis, Eleftherios P
PY - 2004/2/15
Y1 - 2004/2/15
N2 - PURPOSE: Human kallikrein 13 (hK13; encoded by the KLK13 gene) is a secreted serine protease expressed in endocrine tissues, including the prostate, testis, breast, and ovary. We have previously reported steroid hormone regulation of the KLK13 gene and its clinical value as a marker of favorable prognosis in breast cancer at the mRNA level. We hypothesized that hK13 may represent a potential biomarker for ovarian carcinomas.PATIENTS AND METHODS: Using a newly developed enzyme-linked immunosorbent assay (ELISA), hK13 levels were quantified in 131 ovarian tumor extracts and correlated with various clinicopathological variables and outcome (progression-free survival [PFS], overall survival [OS]), over a median follow-up period of 42 months.RESULTS: hK13 concentration in ovarian tumor cytosols ranged from 0 to 18.4 ng/mg of total protein. An optimal cutoff value of 0.13 ng/mg (67(th) percentile) was selected, based on the ability of hK13 values to predict the PFS of the study population, to categorize tumors as hK13-positive or negative. Women with hK13-positive tumors most often had early stage (stage I/II) disease, no residual tumor after surgery and optimal debulking success (P <.05). Univariate and multivariate Cox regression analyses revealed that patients with hK13-positive tumors had a significantly longer PFS and OS than hK13-negative patients (P <.05). Kaplan-Meier survival curves further confirmed a reduced risk of relapse and death in women with hK13-positive tumors (P =.007 and P =.002, respectively).CONCLUSION: These results indicate that hK13 is an independent marker of favorable prognosis in ovarian cancer.
AB - PURPOSE: Human kallikrein 13 (hK13; encoded by the KLK13 gene) is a secreted serine protease expressed in endocrine tissues, including the prostate, testis, breast, and ovary. We have previously reported steroid hormone regulation of the KLK13 gene and its clinical value as a marker of favorable prognosis in breast cancer at the mRNA level. We hypothesized that hK13 may represent a potential biomarker for ovarian carcinomas.PATIENTS AND METHODS: Using a newly developed enzyme-linked immunosorbent assay (ELISA), hK13 levels were quantified in 131 ovarian tumor extracts and correlated with various clinicopathological variables and outcome (progression-free survival [PFS], overall survival [OS]), over a median follow-up period of 42 months.RESULTS: hK13 concentration in ovarian tumor cytosols ranged from 0 to 18.4 ng/mg of total protein. An optimal cutoff value of 0.13 ng/mg (67(th) percentile) was selected, based on the ability of hK13 values to predict the PFS of the study population, to categorize tumors as hK13-positive or negative. Women with hK13-positive tumors most often had early stage (stage I/II) disease, no residual tumor after surgery and optimal debulking success (P <.05). Univariate and multivariate Cox regression analyses revealed that patients with hK13-positive tumors had a significantly longer PFS and OS than hK13-negative patients (P <.05). Kaplan-Meier survival curves further confirmed a reduced risk of relapse and death in women with hK13-positive tumors (P =.007 and P =.002, respectively).CONCLUSION: These results indicate that hK13 is an independent marker of favorable prognosis in ovarian cancer.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Cytosol
KW - Disease-Free Survival
KW - Female
KW - Humans
KW - Kallikreins
KW - Middle Aged
KW - Multivariate Analysis
KW - Ovarian Neoplasms
KW - Proportional Hazards Models
KW - Survival Rate
KW - Tumor Markers, Biological
U2 - 10.1200/JCO.2004.05.144
DO - 10.1200/JCO.2004.05.144
M3 - SCORING: Journal article
C2 - 14966091
VL - 22
SP - 678
EP - 685
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 4
ER -